Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database

OBJECTIVE: To test the hypothesis that exenatide twice daily reduces the relative incidence of cardiovascular disease (CVD) events among patients with type 2 diabetes compared with other glucose-lowering agent(s). RESEARCH DESIGN AND METHODS: A retrospective database analysis was performed of the Li...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Best, Jennie H., Hoogwerf, Byron J., Herman, William H., Pelletier, Elise M., Smith, Daniel B., Wenten, Made, Hussein, Mohamed A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Diabetes Association 2011
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3005487/
https://ncbi.nlm.nih.gov/pubmed/20929995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc10-1393
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi